2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.19 WNT/ß-Catenin Signalling Pathway in Non-Small Cell Lung Cancer: Study of Immuno-expression GSK-3ß, ß-Catenin, And CD44.

EP.06B.19 WNT/ß-Catenin Signalling Pathway in Non-Small Cell Lung Cancer: Study of Immuno-expression GSK-3ß, ß-Catenin, And CD44.

Back to course

Pdf Summary

The study titled "WNT/β-Catenin Signalling Pathway in Non-Small Cell Lung Cancer: Study of Immuno-expression GSK-3β, β-catenin, and CD44" investigates the role of specific proteins associated with the WNT/β-catenin signaling pathway in advanced-stage Non-Small Cell Lung Cancer (NSCLC). Researchers, including Erna Kristiani and colleagues, aimed to uncover how these proteins influence clinicopathological features and the efficacy of platinum-based chemotherapy.<br /><br />Data for this case-control study were retrospectively collected from NSCLC patients at stages III-IV. The study included patients with adenocarcinoma EGFR-wild type and squamous cell carcinoma (SCC) undergoing three cycles of platinum-based chemotherapy. Immunohistochemical (IHC) staining was used to assess GSK-3β, β-catenin, and CD44 expressions in tumor samples, with treatment outcomes evaluated using RECIST criteria. The outcomes were classified into favorable (complete response, partial response, and stable disease) and unfavorable (progressive disease).<br /><br />A total of 62 samples were analyzed, revealing that GSK-3β expression was notably higher in males, patients with stage III cancer, and those with the SCC subtype. Although GSK-3β expression tended to be higher in those with unfavorable responses, and β-catenin and CD44 were higher in favorable responders, these trends were not statistically significant. No significant linear correlations were found among the expression levels of GSK-3β, β-catenin, and CD44.<br /><br />The study underscores the complex relationship between biological markers and clinicopathological traits in NSCLC, suggesting that further research is needed to explore potential therapeutic targets within the WNT/β-catenin signaling pathway.

Asset Subtitle

Erna Kristiani

Meta Tag

Speaker Erna Kristiani

Topic Pathology and Biomarkers

Keywords

WNT/β-catenin signaling pathway

Non-Small Cell Lung Cancer

NSCLC

GSK-3β

β-catenin

CD44

platinum-based chemotherapy

immunohistochemical staining

clinicopathological features

therapeutic targets